Biotechnology Acquisitions in Minnesota

FOXO Technologies Inc., a longevity-focused epigenetics and AI platform for the life insurance industry, completed a business combination with SPAC Delwinds Insurance Acquisition Corp., resulting in FOXO listing on the NYSE American under the ticker FOXO. The transaction positions FOXO to commercialize its molecular biomarkers and saliva-based underwriting protocols and to scale its FOXO Longevity Report and MGA distribution relationships.

Cancer Genetics, Inc. completed a merger with StemoniX, Inc. and renamed the combined company Vyant Bio, Inc., with the new ticker VYNT on Nasdaq. StemoniX will operate as a wholly-owned subsidiary as the combined business integrates human iPSC-derived biology, software and preclinical capabilities to create a unified drug discovery platform.